Apalutamide and Xospata
Determining the interaction of Apalutamide and Xospata and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.GENERALLY AVOID: Coadministration with potent inducers of CYP450 3A4 that also induce P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of gilteritinib, which is a substrate of both the isoenzyme and the efflux transporter. When gilteritinib was coadministered with rifampin, a combined P-gp and potent CYP450 3A4 inducer, gilteritinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 30% and 70%, respectively, compared to administration of gilteritinib alone. Reduced efficacy of gilteritinib may occur. MANAGEMENT: Concomitant use of gilteritinib with combined P-gp and potent CYP450 3A4 inducers should generally be avoided. References "Product Information. Xospata (gilteritinib)." Astellas Pharma US, Inc, Deerfield, IL.
Professional:GENERALLY AVOID: Coadministration with potent inducers of CYP450 3A4 that also induce P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of gilteritinib, which is a substrate of both the isoenzyme and the efflux transporter. When gilteritinib was coadministered with rifampin, a combined P-gp and potent CYP450 3A4 inducer, gilteritinib peak plasma concentration (Cmax) and systemic exposure (AUC) decreased by 30% and 70%, respectively, compared to administration of gilteritinib alone. Reduced efficacy of gilteritinib may occur.
MANAGEMENT: Concomitant use of gilteritinib with combined P-gp and potent CYP450 3A4 inducers should generally be avoided.
- "Product Information. Xospata (gilteritinib)." Astellas Pharma US, Inc, Deerfield, IL.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.